Pharmaceuticals

Alphamab Oncology Announced First Patient Dosed in the U.S. in A Phase II Pivotal Clinical Study of KN046

SUZHOU, China, Dec. 23, 2021 /PRNewswire/ -- Alphamab Oncology (stock code: 9966 HK) announced dosing of the first patient of its proprietary PD-L1/CTLA-4 bispecific antibody KN046 inthe United States. The patient received treatment in ENREACH-Thymic, a phase II, open label, multi-center pivotal...

2021-12-23 09:13 2882

Lion TCR Receives FDA Fast Track Designation for its HBV-specific TCR T Cell Therapy for Hepatocellular Carcinoma

SINGAPORE and GUANGZHOU, China and LOS ANGELES, Dec. 23, 2021 /PRNewswire/ -- Lion TCR Pte Ltd today announced that it has received Fast Track Designation from United States Food and Drug Administration (U.S. FDA) for LioCyx-M004, autologous T-cells transfected with mRNA encoding Hepatitis B surf...

2021-12-23 09:00 2579

LINEPHARMA INTERNATIONAL FILES FOR MANUFACTURING, MARKETING APPROVAL OF THE ABORTION PILL IN JAPAN

LONDON and TOKYO, Dec. 23, 2021 /PRNewswire/ -- Linepharma International Ltd., a global leader in medical abortion, announced today that its subsidiary Linepharma KK has applied for manufacturing and marketing approval inJapan for its oral drug MEFEEGO™ for the medical termination of pregnancies ...

2021-12-23 05:57 2287

Karyopharm and Menarini Group Enter into Exclusive License Agreement to Commercialize NEXPOVIO® (selinexor) in Europe and Other Key Global Territories

- Menarini Group Obtains Exclusive Rights to Commercialize NEXPOVIO for the Treatment of Hematologic and Solid Tumor Oncology Indications inEurope (including theUnited Kingdom), Latin America and Other Key Countries - Karyopharm to Receive $75 Million Upfront, then Eligible to Receive Up to $202...

2021-12-22 09:39 2810

World Health Organization SAGE Issues Interim Recommendations for Novavax COVID-19 Vaccine

- WHO Strategic Advisory Group of Experts on Immunization (SAGE) recommends primary two-dose vaccination series of NVX-CoV2373 in persons aged 18 and older - SAGE recommends additional third dose of NVX-CoV2373 administered to immunocompromised persons - Recommendation follows grant of WHO Emerg...

2021-12-22 09:31 2998

MSD Romania recognized as one of the Best Workplaces for 2021

BUCHAREST, Romania, Dec. 21, 2021 /PRNewswire/ -- MSD Romania, an affiliate of the American multinational pharmaceutical company developing and producing medicines, vaccines, biologic therapies, animal health products, have been certified as one of the Best Places to Work for 2021. This certifica...

2021-12-21 21:05 1420

Novaliq Announces POSITIVE Topline Results for SECOND PHASE 3 TRIAL (ESSENCE-2) of CyclASol® in Dry Eye Disease

HEIDELBERG, Germany and CAMBRIDGE, Mass, Dec. 21, 2021 /PRNewswire/ -- Novaliq, a biopharmaceutical company focusing on first- and best-in-class ocular therapeutics based on the unique EyeSol® water-free technology, today announced key results of the second pivotal Phase 3 trial (ESSENCE-2) evalu...

2021-12-21 21:00 1636

CSTONE ANNOUNCED NEW DRUG APPROVAL OF CEJEMLY® (SUGEMALIMAB) IN CHINA TO POTENTIALLY RESHAPE THE LANDSCAPE OF IMMUNO-ONCOLOGY THERAPY IN LUNG CANCER

SUZHOU, China, Dec. 21, 2021 /PRNewswire/ -- CStone Pharmaceuticals (the " Company" or "CStone") is pleased to announce that the National Medical Products Administration ("NMPA") of China has approved the new drug application ("NDA") of anti-PD-L1 monoclonal antibody Cejemly® (sugemalimab) in comb...

2021-12-21 16:56 2687

World Health Organization Grants Second Emergency Use Listing for Novavax COVID-19 Vaccine

- Nuvaxovid™ COVID-19 Vaccine (SARS-CoV-2 rS [Recombinant, adjuvanted]) listed for emergency use by the WHO - EUL for Nuvaxovid complements listing for Novavax vaccine manufactured and marketedby Serum Institute of India as Covovax™ - EUL by WHO is a prerequisite for exports to numerous countri...

2021-12-21 03:33 2596

Everest Medicines and Providence Therapeutics announces that PTX-COVID19-B, a mRNA Vaccine for COVID-19, has received approval for inclusion in WHO Solidarity Trial Vaccines (STV) Program

SHANGHAI, Dec. 20, 2021 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK) and Providence Therapeutics ("Providence") announced today that their COVID-19 vaccine, PTX-COVID19-B, has been recommended by an independent advisory group to be part of the WHO Solidarity Trial Vaccines ("STV") clinical t...

2021-12-20 20:55 2945

2021 Sustainability Report of Sai Life Sciences highlights the momentum gained in its Sustainability choices

* Report developed as per Global Reporting Initiative (GRI) standards * Extensively deals with the company's response to the Covid-19 pandemic HYDERABAD, India, Dec. 20, 2021 /PRNewswire/ -- Sai Life Sciences, a leading globalContract Research, Development & Manufacturing Organization

2021-12-20 19:16 827

First Patient Dosed in Australia in ATG-101 First-in-Human Trial

SHANGHAI and HONG KONG, Dec. 20, 2021 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class therapeutics in hematology and onco...

2021-12-20 11:01 3264

Japan's MHLW Approves Booster Shot for SPIKEVAX®, Moderna's mRNA COVID-19 Vaccine

The SPIKEVAX® brand name was developed in partnership with Brand Institute, the global leader in pharmaceutical and healthcare-related name development MIAMI, Dec. 20, 2021 /PRNewswire/ -- Brand Institute is proud to announce its successful partnership with Moderna in naming their mRNA COVID-19 v...

2021-12-20 09:00 2513

Westlake Omics Authorized as the Exclusive Distributor and Service Provider of Pressure BioSciences, Inc. in China

HANGZHOU, China, Dec. 17, 2021 /PRNewswire/ -- The Agreement signed by Westlake Omics (Hangzhou) Biotechnology Co., Ltd (hereinafter referred to as Westlake Omics) and Pressure BioSciences, Inc. (hereinafter referred to as PBI) on December 3, 2021 authorized Westlake Omics as the exclusive distrib...

2021-12-17 19:00 1833

Bioscience Animal Health Public Company Limited Accorded the International Innovation Awards 2021 for Angentex® COVID-19 qPCR Detection Kit

SINGAPORE, Dec. 17, 2021 /PRNewswire/ -- Enterprise Asia is pleased to honor 52 award recipients at the International Innovation Awards 2021. Spearheading the Innovation Revolution, the International Innovation Awards which aims to create an innovation ecosystem for enterprises is held annually t...

2021-12-17 18:24 1886

Study on Anti-aging with TCM Strides Forward

SHIJIAZHUANG, China, Dec. 17, 2021 /PRNewswire/ -- The opinions of experts on "Study on Anti-aging with Bazi Bushen Capsules Guided by Qi Collateral Theory" were released inShijiazhuang, Hebei on December 15. According to the opinions, the preliminary research of the project has created the theo...

2021-12-17 17:06 2128

Lipidor expands clinical program, announces investment in new drug development project against acne vulgaris

STOCKHOLM, Dec. 17, 2021 /PRNewswire/ -- Lipidor AB (publ) (Nasdaq First North: LIPI) today announces that it has initiated a preclinical program for a new drug candidate, AKP-08, focused on acne vulgaris (acne). The market for acne medicines amounts to about35 billion SEK per year, which togethe...

2021-12-17 16:10 1772

Transcenta Announces the Appointment of Daniel Weng as CFO

SUZHOU, China, Dec. 17, 2021 /PRNewswire/ -- Transcenta Holding Limited ("Transcenta") (HKEX: 06628), a clinical stage biopharmaceutical company with fully-integrated capabilities in discovery, research, development and manufacturing of antibody-based therapeutics, announces the appointment of Da...

2021-12-17 08:30 3270

BioWorld by Clarivate Identifies the Top Six Global Biopharmaceutical Stories and Trends of 2021

Advances in Alzheimer's, innovation in DNA vaccines, increased regulatory collaboration and the evolving impact of Artificial Intelligence, join Covid-19 as key stories and trends of 2021 LONDON, Dec. 16, 2021 /PRNewswire/ -- BioWorld published by Clarivate Plc  (NYSE:CLVT), a global leader in pr...

2021-12-16 16:14 2088

Debiopharm Further Explores the Potential of its Potent, Highly Selective WEE1 Inhibitor Debio 0123 In Phase 1 Cancer Study

Dose escalation, monotherapy trial launched to access the safety and preliminary anti-tumor activity of Debio 0123 in the treatment of advanced solid tumors LAUSANNE, Switzerland, Dec. 16, 2021 /PRNewswire/ -- Debiopharm ( www.debiopharm.com ), a Swiss biopharmaceutica...

2021-12-16 16:00 1747
1 ... 93949596979899 ... 181